Tarsa Therapeutics, Inc. was founded in 2009 with the goal of developing innovative therapies for the treatment and prevention of osteoporosis and related bone diseases. Tarsa is developing TBRIA™ an oral formulation of salmon calcitonin, which is a peptide hormone that inhibits bone resorption, a key process underlying the development of osteoporosis.